Avidity Biosciences Inc (RNA)

May 21, 2025

Avidity Biosciences Expands Team with $2.2M Stock Package: 16 New Hires Signal Growth - Stock Titan

May 21, 2025

May 20, 2025

Avidity Biosciences Target of Unusually Large Options Trading (NASDAQ:RNA) - Defense World

May 20, 2025

May 16, 2025

Stifel Financial Corp Cuts Stake in Avidity Biosciences, Inc. (NASDAQ:RNA) - Defense World

May 16, 2025

May 16, 2025

HC Wainwright Analysts Reduce Earnings Estimates for RNA - Defense World

May 16, 2025

May 15, 2025

FY2025 EPS Estimates for RNA Lowered by Cantor Fitzgerald - Defense World

May 15, 2025

May 14, 2025

When (RNA) Moves Investors should Listen - news.stocktradersdaily.com

May 14, 2025

May 14, 2025

Avidity Biosciences Reports Q1 2025 Earnings - TipRanks

May 14, 2025

May 13, 2025

Transcript : Avidity Biosciences, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 03 - marketscreener.com

May 13, 2025

May 13, 2025

Avidity Biosciences (NASDAQ:RNA) Price Target Cut to $68.00 by Analysts at HC Wainwright - Defense World

May 13, 2025

May 12, 2025

Avidity Biosciences to Participate in Upcoming Investor Conference - Kilgore News Herald

May 12, 2025

May 12, 2025

Avidity Biosciences (RNA) Target Price Lowered by HC Wainwright & Co. | RNA Stock News - GuruFocus

May 12, 2025

May 10, 2025

Avidity Biosciences Announces Upcoming Presentations at 2023 Myo - GuruFocus

May 10, 2025

May 10, 2025

Avidity Biosciences First Quarter 2025 Earnings: Misses Expectations - Yahoo Finance

May 10, 2025

May 10, 2025

Avidity Biosciences’ (RNA) Buy Rating Reiterated at Chardan Capital - Defense World

May 10, 2025

May 09, 2025

Avidity Biosciences (RNA) Receives Buy Rating from Chardan Capital | RNA Stock News - GuruFocus

May 09, 2025

May 09, 2025

Avidity Biosciences Reports First Quarter 2025 Financial Results and Recent Highlights - BioSpace

May 09, 2025

May 08, 2025

Avidity Biosciences, Inc. (RNA) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance

May 08, 2025

May 07, 2025

12 Analysts Assess Avidity Biosciences: What You Need To Know - Benzinga

May 07, 2025

May 06, 2025

RNA Therapeutics Pioneer Avidity Biosciences Takes Stage at Major Bank of America Healthcare Conference - Stock Titan

May 06, 2025

May 04, 2025

(RNA) Investment Report - news.stocktradersdaily.com

May 04, 2025

May 03, 2025

Avidity Biosciences chief program officer sells $190k in stock By Investing.com - Investing.com South Africa

May 03, 2025

May 03, 2025

Avidity Biosciences chief program officer sells $190k in stock - Investing.com Australia

May 03, 2025

May 02, 2025

Envestnet Asset Management Inc. Lowers Position in Avidity Biosciences, Inc. (NASDAQ:RNA) - Defense World

May 02, 2025

Apr 30, 2025

Avidity Biosciences appoints Deloitte as new auditor By Investing.com - Investing.com Canada

Apr 30, 2025

Apr 29, 2025

Avidity Biosciences appoints Deloitte as new auditor - Investing.com

Apr 29, 2025

Apr 27, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 27, 2025

Apr 22, 2025

Avidity Biosciences' RNA Drug for DM1 Gains Orphan Status in Jap - GuruFocus

Apr 22, 2025

Apr 21, 2025

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Financial Times

Apr 21, 2025

Apr 20, 2025

Federated Hermes Inc. Decreases Stake in Avidity Biosciences, Inc. (NASDAQ:RNA) - Defense World

Apr 20, 2025

Apr 18, 2025

Avidity Biosciences Plans First BLA Submission and Accelerates Commercialization Preparations for Three Rare Muscle Disease Programs in 2025 (PR Newswire) - Aktiellt

Apr 18, 2025

Apr 15, 2025

Avidity’s del-desiran for DM1 named orphan drug in Japan - Muscular Dystrophy News

Apr 15, 2025

Apr 09, 2025

Beyond The Numbers: 13 Analysts Discuss Avidity Biosciences Stock - Benzinga

Apr 09, 2025

Apr 08, 2025

Japan grants Avidity’s DM1 drug Orphan status By Investing.com - Investing.com South Africa

Apr 08, 2025

Apr 08, 2025

Avidity Biosciences Receives Orphan Drug Designation in Japan for Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1 - StreetInsider

Apr 08, 2025

Apr 08, 2025

Avidity Biosciences Receives Orphan Drug Designation in Japan fo - GuruFocus

Apr 08, 2025

Apr 08, 2025

Avidity Says Japan Grants Orphan Drug Status to Del-Desiran for Myotonic Dystrophy Type 1 - marketscreener.com

Apr 08, 2025

Apr 08, 2025

Japan grants Avidity's DM1 drug Orphan status By Investing.com - Investing.com India

Apr 08, 2025

Apr 08, 2025

Japan grants Avidity's DM1 drug Orphan status - Investing.com

Apr 08, 2025

Apr 08, 2025

Avidity Biosciences Receives Orphan Drug Designation In Japan For Delpacibart Etedesiran - MarketScreener

Apr 08, 2025

Apr 07, 2025

Myotonic Dystrophy Pipeline Analysis and Clinical Trials - openPR.com

Apr 07, 2025

Apr 06, 2025

Avidity Biosciences chief program officer sells shares worth $206,799 - MSN

Apr 06, 2025

Apr 06, 2025

Avidity Biosciences CFO sells $93,985 in stock - MSN

Apr 06, 2025

Apr 05, 2025

Avidity Biosciences (RNA): Among Unstoppable Stocks That Could Double Your Money - MSN

Apr 05, 2025

Apr 03, 2025

Avidity Biosciences’ chief program officer sells $163k in stock - Investing.com India

Apr 03, 2025

Apr 03, 2025

Avidity Biosciences’ chief program officer sells $163k in stock By Investing.com - Investing.com UK

Apr 03, 2025

Apr 03, 2025

Avidity Biosciences (RNA) Soars 11.3%: Is Further Upside Left in the Stock? - Nasdaq

Apr 03, 2025